Abstract:OBJECTIVE To explore the effects of pioglitazone on insulitis and diabetes and relevant mechanism. METHODS Seventy-three female non-obese diabetic (NOD)/Lt mice aged 4 weeks were randomly divided into 3 groups, control group (n = 25, fed with regular diet), low dosage pioglitazone group (n = 23, pioglitazone of the concentration of 0.01% was added into the feed) and high dosage pioglitazone group (n = 25, pioglitazone of the concentration of 0.04% was added into the feed). The mice were killed when diabetes developed or they reached the age of 30 weeks. The body weight and amount of food intake were measured every week and the amount of drug intake was calculated. Urine glucose was checked weekly from week 10 to week 30. When urine glucose was positive and relevant symptoms appeared, blood glucose was measured. The criterion of diagnosis of diabetes was the consecutive blood glucose level > or = 16.7 mmol/L for 2 times. At the 12th week 4-7 mice from the 3 groups respectively were killed and their pancreases were removed to be scored on insulitis by HE staining, the spleen cells were cultured. The IL-4 and IFN-r levels in serum and supernatants of spleen cell cultures were measured by ELISA. The pancreatic IFN-r mRNA level was tested using RT-PCR method. RESULTS (1) At the age of 30 weeks, the diabetes incidence rates was 80% (20/25) in the control group, 60.9% (14/23) in the low dose group, and 60% (15/25) in the high dose group (P > 0.05). At the following time points the diabetes incidence rates of the 2 treated groups were lower than that of the control group (all P < 0.05): (1) 0% in the low dose group vs 16%: of the control group at the age of 100 days, and 39% vs 68% at the age of 185 days; and (2) 0% in the high dose group vs 16% in the control group at the age of 110 days, 4% vs 24% at the age of 120 days, and 12%vs 36% at the age of 135 days. (2) There was no difference in insulitis scores between the control group and low dose or high dose groups at the age of 12 weeks (1.99 +/- 0.75 vs 1.01 +/- 0.68 and 1.19 +/- 0.84, both P > 0.05), however, the score of the combined pioglitazone group (low dose group + high dos group) was significantly higher than that of the control group (1.12 +/- 0.75 vs 1.99 +/- 0.75, P < 0.05). (3) There was no differences in the IL-4/IFN-r ratios in serum and splenocyte culture supernatant and pancreatic IFN-r mRNA levels among the three groups (all P > 0.05). CONCLUSION Pioglitazone, to some extent, lessens the insulitis severity and delays the diabetes onset. Its mechanism may be unrelated to immune deviation of Th1 to a Th2.

Pioglitazone Attenuates Cognitive Impairment Induced by Intracerebroventricular Streptozotocin Injection in Mice and Underlying Mechanisms

Pioglitazone Ameliorates Memory Deficits In Streptozotocin-Induced Diabetic Mice By Reducing Brain Beta-Amyloid Through Ppar Gamma Activation

Pioglitazone Ameliorates Memory Deficits in Streptozotocin-Induced Diabetic Mice by Reducing Brain Β-Amyloid Through PPARγ Activation.

Rosiglitazone Improves Cognitive Impairment in Streptozotocin-induced Diabetic Mice and its Mechanisms

Expression Changes of Growth-Associated Protein-43 (Gap-43) and Mitogen-Activated Protein Kinase Phosphatase-1 (Mkp-1) and in Hippocampus of Streptozotocin-Induced Diabetic Cognitive Impairment Rats

Effect of Pioglitazone on the spatial memory and hippocampal structure in model of SAD rates

PPARγ Agonist Pioglitazone Improves Scopolamine-Induced Memory Impairment in Mice.

PPARγ agonist pioglitazone reverses memory impairment and biochemical changes in a mouse model of type 2 diabetes mellitus.

Pioglitazone Attenuates Ischaemic Stroke Aggravation by Blocking PPARγ Reduction and Inhibiting Chronic Inflammation in Diabetic Mice.

Effects of pioglitazone on cognitive impairments induced by isoflurane anesthesia in aged mice

Effect and Mechanism of Auricularia Auriculajudae Polysaccharide in Hippocampus of Streptozotocin‐induced Diabetic Cognitive Impairment Rats

Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice

[Preventive Effects of Pioglitazone on Diabetes and Relevant Mechanisms, Experimental Study on Non-Obese Diabetic Mice].

Pioglitazone alleviates the mitochondrial apoptotic pathway and mito-oxidative damage in the d-galactose-induced mouse model

Tirzepatide ameliorates spatial learning and memory impairment through modulation of aberrant insulin resistance and inflammation response in diabetic rats

Valsartan Improves the Cognition Impairment in Diabetic Mice and Underlying Mechanism

Effects of Pioglitazone on MKP-1 and TSP-1 Expression in Early Stages of Diabetic Retinopathy Induced by Streptozotocin

Effects of Analog P165 of Amyloid Precursor Protein 5-Mer Peptide on Learning, Memory and Brain Insulin Receptors in the Rat Model of Cognitive Decline.

Effects of paeoniflorin on neurobehavior, oxidative stress, brain insulin signaling, and synaptic alterations in intracerebroventricular streptozotocin-induced cognitive impairment in mice

Influence of Pioglitazone on Renal Mitochondrial Oxidative Stress in Diabetic Rats

Effect of pioglitazone on endothelial function in elderly patients with impaired glucose tolerance